Kyte, Derek ORCID: https://orcid.org/0000-0002-7679-6741, Anderson, N., Bishop, J., Bissell, A., Brettell, E., Calvert, M., Chadburn, M., Cockwell, P., Dutton, M., Eddington, H., Forster, E., Hadley, G., Ives, N. J., Jackson, L. J., O'Brien, S., Price, G., Sharpe, K., Stringer, S., Verdo, R., Waters, J. and Wilcockson, A. (2022) Results of a pilot feasibility randomised controlled trial exploring the use of an electronic patient-reported outcome measure in the management of UK patients with advanced chronic kidney disease. BMJ Open, 12 (e05061). ISSN Online: 2044-6055
Preview |
Text (Open Access article)
e050610.full.pdf - Published Version Available under License Creative Commons Attribution. Download (649kB) | Preview |
Abstract
Objectives The use of routine remote follow-up of patients with chronic kidney disease (CKD) is increasing exponentially. It has been suggested that online electronic patient-reported outcome measures (ePROMs) could be used in parallel, to facilitate real-time symptom monitoring aimed at improving outcomes. We tested the feasibility of this approach in a pilot trial of ePROM symptom monitoring versus usual care in patients with advanced CKD not on dialysis.
Design A 12-month, parallel, pilot randomised controlled trial (RCT) and qualitative substudy.
Setting and participants Queen Elizabeth Hospital Birmingham, UK. Adult patients with advanced CKD (estimated glomerular filtration rate ≥6 and ≤15 mL/min/1.73 m2, or a projected risk of progression to kidney failure within 2 years ≥20%).
Intervention Monthly online ePROM symptom reporting, including automated feedback of tailored self-management advice and triggered clinical notifications in the advent of severe symptoms. Real-time ePROM data were made available to the clinical team via the electronic medical record.
Outcomes Feasibility (recruitment and retention rates, and acceptability/adherence to the ePROM intervention). Health-related quality of life, clinical data (eg, measures of kidney function, kidney failure, hospitalisation, death) and healthcare utilisation.
Results 52 patients were randomised (31% of approached). Case report form returns were high (99.5%), as was retention (96%). Overall, 73% of expected ePROM questionnaires were received. Intervention adherence was high beyond 90 days (74%) and 180 days (65%); but dropped beyond 270 days (46%). Qualitative interviews supported proof of concept and intervention acceptability, but highlighted necessary changes aimed at enhancing overall functionality/scalability of the ePROM system.
Limitations Small sample size.
Conclusions This pilot trial demonstrates that patients are willing to be randomised to a trial assessing ePROM symptom monitoring. The intervention was considered acceptable; though measures to improve longer-term engagement are needed. A full-scale RCT is considered feasible.
Trial registration number ISRCTN12669006 and the UK NIHR Portfolio (CPMS ID: 36497).
Item Type: | Article |
---|---|
Additional Information: | Data are available on reasonable request. The datasets used and/or analysed during the current study are available from the Birmingham Clinical Trials Unit on reasonable request via the corresponding author. https://creativecommons.org/licenses/by/4.0/ Supplementary materials available: https://bmjopen.bmj.com/content/12/3/e050610 |
Divisions: | College of Health, Life and Environmental Sciences > School of Allied Health and Community |
Related URLs: | |
Copyright Info: | © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. |
Depositing User: | Derek Kyte |
Date Deposited: | 19 Apr 2022 15:04 |
Last Modified: | 19 Apr 2022 15:09 |
URI: | https://worc-9.eprints-hosting.org/id/eprint/11961 |
Actions (login required)
View Item |